ASH Conference Coverage
Featured Articles
(EP Vantage) Dec 12, 2017 - Juno had hoped that the Ash meeting would mark its return as a competitive force in CAR-T. Instead, a keenly awaited update of its now pivotal lymphoma trial, Transcend, disappointed, and yesterday’s 14% share price collapse marked the second year in a row that Ash left the company nursing heavy losses.
Read Article
(Morningstar) Dec 14, 2017 - BioSight Ltd, a pharmaceutical development company, focused on the development of targeted oncology drugs, reports positive final results in a Phase I/II multi-center, open label, dose-escalating study of its lead product BST-236, a novel cytarabine pro-drug, as a single agent for induction therapy in acute...
Read Article
Latest Articles
December 14, 2017
December 14, 2017
December 13, 2017
December 13, 2017
December 13, 2017
December 13, 2017
December 13, 2017
December 13, 2017
View More
News Commentary
There is no ASH Conference Coverage commentary.

OBR Green
There are no ASH Conference Coverage OBR Green articles.
OBR Blog
There are no ASH Conference Coverage blog entries.